Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Orexigen Rises as Weight Loss Drug Review Proceeds

By Pharmaceutical Processing | November 10, 2014

NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.

Orexigen said it still having talks with an advisory committee about Contrave. It will send the committee more information about the drug in November and expects the group to give its opinion in December. Orexigen wants to market the drug in Europe under the name Mysimba.

Orexigen also reported better-than-expected quarterly results, and its shares picked up 69 cents, or 17.9 percent, to $4.54 in morning trading.

The U.S. Food and Drug Administration approved Contrave in September after more than two years of delays. Regulators were concerned about the effect of the drug on patients’ cardiovascular systems, and asked Orexigen to do more research into the issue.

Contrave is a combination of two drugs that are already approved: naltrexone, which is used to treat alcohol and narcotic dependence, and bupropion, an antidepressant also used to help people quit smoking. The drug will be distributed in the U.S. by Japanese drugmaker Takeda Pharmaceuticals, which will pay Orexigen royalties on sales. Orexigen and Takeda plan to start selling the drug this fall.

Takeda paid Orexigen $30 million in the third quarter after approval as it got ready to launch Contrave, and Orexigen says it received another $70 million early in the fourth quarter.

The La Jolla, California, company reported a profit of $11.3 million, or 9 cents per share, in the third quarter on revenue of $30.9 million.

Zacks Investment Research says analysts expected net income of 5 cents per share.

A year ago Orexigen posted a loss of $18.6 million, or 19 cents per share, on revenue of $857,000.

Contrave is the third weight loss drug to be approved in recent years. The FDA approved Vivus Inc.’s Qsymia and Arena Pharmaceuticals Inc.’s Belviq in 2012, but sales of both products have been far below expectations due to limited insurance coverage and high out-of-pocket costs for patients.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE